Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    IMUC   US4525361055

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
01/22/2015 01/23/2015 01/26/2015 01/27/2015 01/28/2015 Date
0.6814(c) 0.68(c) 0.6789(c) 0.7(c) 0.68(c) Last
290 096 135 015 172 672 78 907 274 721 Volume
-2.66% -0.21% -0.16% +3.11% -2.86% Change
More quotes
Company
ImmunoCellular Therapeutics Ltd. is a clinical-stage biotechnology company, which focuses on developing immune-based therapies for the treatment of brain and other cancers.Its cell-based vaccine technologies are primary platform technologies and commercial prospects will be heavily dependent on the... 
Sector
Biotechnology & Medical Research
Calendar
02/09 | 02:00pmPresentation
More about the company
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | IMUC | US4525361055 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 -
EBIT 2014 -10,5 M
Net income 2014 -10,1 M
Debt 2014 -
Yield 2014 -
Sales 2015 -
EBIT 2015 -16,7 M
Net income 2015 -16,6 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 0
Capi. / Sales 2015 0
Capitalization 43,9 M
More Financials
Latest news on IMMUNOCELLULAR THERAPEUTIC
06:01a IMMUNOCELLULAR THERAPEUTICS : to Present at the BIO CEO & Investor Conference on..
2014 IMMUNOCELLULAR THERAPEUTICS : Html pdf
2014 IMMUNOCELLULAR THERAPEUTICS : Announces Issuance of Key Patent For ICT-107 Cance..
2014 IMMUNOCELLULAR THERAPEUTICS : gets EMA positive regulatory feedback on advancing..
2014 IMMUNOCELLULAR THERAPEUTICS : Receives Positive Regulatory Feedback from Europea..
2014 IMMUNOCELLULAR THERAPEUTICS : Announces Third Quarter 2014 Financial Results
2014 IMMUNOCELLULAR THERAPEUTICS : Regulation FD Disclosure, Other Events, Financial ..
2014 IMMUNOCELLULAR THERAPEUTICS : Presents Updated ICT-107 Phase II Data at the Soci..
More news
Sector news Biotechnology & Medical Research - NEC
05:01p INCYTE : Announces Publication of Phase III RESPONSE Trial in Patients with Poly..
04:01p QIAGEN NV : Reports Results for Fourth Quarter and Full-Year 2014
01/27 QIAGEN NV : Introduces QuantiFERON Monitor® for Tracking Immune Function in Soli..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF